Baxter BioPharma Solutions and SAFC Collaborate on Complete ADC Offering

Baxter’s BioPharma Solutions (BPS) business and Sigma-Aldrich Corporation’s SAFC® Custom Manufacturing Services business unit, have established a collaborative manufacturing agreement. As part of the terms of the agreement, SAFC will contribute extensive expertise in conjugation and the manufacture of drug linkers, while BioPharma Solutions will offer world-class, sterile fill/finish services for final filling of Antibody-drug Conjugate (ADC) products.

ADCAntibody-drug conjugation technology uses monoclonal antibodies or other biologics to deliver conjugated Highly-Active Pharmaceutical Ingredients or HAPIs to a specific target. In conjugated form, these new drug exhibits more selective cytotoxicity, which results in sparing non-target cells from many of the unwanted toxic (side) effects. New ADCs that are being developed are more targeted and exponentially more powerful.

In today’s market, pharmaceutical industry customers require flexibility, reliability and quality from their Contract Manufacturing Organization (CMO). Industry watchers confirm that many industry players also expect a single solution for their ADC development.

Lonza
MabPlex
ADC Bio
 

The  collaboration between Baxter and SAFC brings two providers of critical-care products and services together to provide their customers with a secure and simplified supply chain, as well as a comprehensive, coordinated and collaborative services for the development, manufacturing, and testing of bulk drug substance and drug products. Both companies have hands-on experience with more than 20 different ADC constructs.  The companies have also dedicated facilities that are SafeBridge Certified to handle Category 4 compounds, allowing them to get Antibody-drug Conjugate products to the market faster.

Previous articleMerck KGaA acquires Sigma-Aldrich
Next articleImproved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated with Vintafolide
ADC Review
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.